Characterising individual response to mepolizumab treatment

被引：0
|
作者：
Jackson, David [1 ,2 ]
Price, Robert G. [3 ]
Yancey, Steven W. [4 ]
Buhl, Roland [5 ]
Wenzel, Sally [6 ]
机构：
[1] Kings Coll London, Guys Severe Asthma Ctr, Guys & St Thomas NHS Trust, London, England
[2] Kings Coll London, Sch Immunol & Microbial Sci, Asthma UK Ctr, London, England
[3] GSK, Biostat, Stevenage, Herts, England
[4] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA
[5] Mainz Univ Hosp, Pulm Dept, Mainz, Germany
[6] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Treatments; Asthma; -; management; Severe asthma;
D O I：
10.1183/13993003.congress-2020.2259
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2259
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Response To Treatment With Mepolizumab In Elderly Patients
    Ortega, H.
    Mayer, B.
    Yancey, S.
    Katial, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [2] Durability of mepolizumab treatment response between doses
    Pavord, Ian Douglas
    Howarth, Peter
    Bratton, Daniel J.
    Albers, Frank C.
    Yancey, Steven
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [3] Evaluating treatment response to mepolizumab in patients with severe CRSwNP
    Hopkins, Claire
    Han, Joseph K.
    Lund, Valerie J.
    Bachert, Claus
    Fokkens, Wytske J.
    Diamant, Zuzana
    Mullol, Joaquim
    Sousa, Ana R.
    Smith, Steven G.
    Yang, Shibing
    Mayer, Bhabita
    Yancey, Steve W.
    Chan, Robert H.
    Lee, Stella E.
    RHINOLOGY, 2023, 61 (02) : 108 - 117
  • [4] Clinical indicators of treatment response to Mepolizumab at 12 weeks
    Pang, Yik Lam
    Stewart, Iain
    Harrison, Tim
    Sayers, Ian
    Shaw, Dominick
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [5] Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
    Pavord, Ian D.
    Buhl, Roland
    Kraft, Monica
    Prazma, Charlene M.
    Price, Robert G.
    Howarth, Peter H.
    Yancey, Steven W.
    ERJ OPEN RESEARCH, 2022, 8 (02)
  • [6] Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
    Magnan, A.
    Bourdin, A.
    Prazma, C. M.
    Albers, F. C.
    Price, R. G.
    Yancey, S. W.
    Ortega, H.
    ALLERGY, 2016, 71 (09) : 1335 - 1344
  • [7] Mepolizumab treatment for asthma
    Robinson, Douglas S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) : 295 - 302
  • [8] Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
    Prazma, Charlene M.
    Idzko, Marco
    Douglass, Jo Anne
    Bourdin, Arnaud
    Mallett, Stephen
    Albers, Frank C.
    Yancey, Steven W.
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 675 - 683
  • [9] Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps
    Tan, Nadia Suray
    Ong, Yew Kwang
    Mukherjee, Manali
    Chao, Siew Shuen
    Tan, W. S. Daniel
    Liew, Mei Fong
    Xu, Xinni
    Sng, Yuansheng Melvin
    Wang, De Yun
    Wong, W. S. Fred
    Nair, Parameswaran
    Angeli, Veronique
    Lim, Hui Fang
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [10] The influence of Adherence to inhaled Corticosteroids (ICS) on treatment Response to mepolizumab treatment in severe Eosinophilic asthma
    Almutairi, Mohammed
    Marriott, John
    Jalal, Zahraa
    Wood, Louise
    Almoosawi, Batool
    Caddick, Samantha
    Rajkumari, Babita
    Renwick, Susan
    Wilkinson, Siobhan
    Gallagher, Caroline
    Duffin, Thomas
    Mansur, Adel
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345